Bio-gene Technology Ltd. · ASX:BGT
Bio-gene Technology — Investor Presentation (October 2021)
12 slides from Bio-gene Technology's investor presentation, Oct 28, 2021
Slide 1: Enabling the Next Generation of Novel Insecticides
BIO-GENE For personal use only TECHNOLOGY LIMITED ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES OCTOBER 2021 INVESTOR UPDATE PRESENTED BY Richard Jagger Chief Executive Officer & Managing Director
Slide 2: Disclaimer
DISCLAIMER This presentation has been prepared by Bio-Gene Technology Limited (ASX:BGT) (the Company). This presentation is not, and should not be considered, an offer or invitation to For personal use only apply for or purchase securities in the Company or as a recommendation or inducement to make
Slide 3: Significant positive progress across multiple fronts
Significant positive New agreements with commercial partners For personal use only progress across Development agreements BGT has executed a commercial development agreement with Evergreen Garden Care and has negotiated an exclusive option with Clarke Mosquito multiple fronts Control Additional MTAs
Slide 4: Bio-Gene announces commercial deal with Evergreen Garden Care
BIO-GENE ANNOUNCES COMMERCIAL DEAL WITH EVERGREEN GARDEN CARE For personal use only Evergreen is a market leader in consumer products across Europe and in Australia/New Zealand marketing major brands such as: “We are excited to be partnering with Bio-Gene to develop natural consumer pest control pro
Slide 5: Evergreen commercial development agreement
EVERGREEN COMMERCIAL DEVELOPMENT AGREEMENT For personal use only Initial Field of Use Initial Territory Market Segment Fly & mosquito electric evaporator European Union, United Kingdom, Consumer products Initial Ant bait gel and ant spray Norway, Switzerland, Australia, Term applications New Zealand
Slide 6: New option agreement signed on Clarke Mosquito project
NEW OPTION AGREEMENT SIGNED ON CLARKE MOSQUITO For personal use only PROJECT Results of Phase 2 Testing New Option Agreement Signed Next Steps Very positive results indicate the 90 Days to complete full Clarke to confirm timing for the suitability of Bio-Gene products as commercial terms field compo
Slide 7: Update on BASF stored grain project
UPDATE ON BASF STORED GRAIN PROJECT For personal use only Details of Current Agreement Results of Phase 3 Testing Next Stage with BASF Field testing will be completed Involves commitment to the Term of exclusivity to have option Nov/Dec 2021 regulatory studies required for Studies to date show for s
Slide 8: Manufacturing & regulatory update
MANUFACTURING & REGULATORY UPDATE For personal use only Flavocide Qcide Next Steps ▪ Flavocide manufacturing • Last harvest confirmed • Finalisation of the Flavocide 5 validation – scale-up process production improvements batch production and analysis has confirmed ability to produce based on modifi
Slide 9: Important progress across other areas
IMPORTANT PROGRESS ACROSS OTHER AREAS For personal use only Efficacy: Crop Pests Efficacy: Non-crop Pests • Final stage of CRO testing underway • Additional studies underway for specific • Focus is on a range of key commercial company evaluation of technology On-going research species, targeting pot
Slide 10: Funding position
FUNDING POSITION For personal use only Sources of future funding: Shares on issue 152, 619, 401 Market capitalisation $29.8 million1 Development Government Philanthropic As at September 30, 2021, and commercial grants organisations Cash on hand partnerships focused on public health solutions A$3.2 m
Slide 11: Key investment highlights
KEY INVESTMENT For personal use only HIGHLIGHTS Proprietary insecticide Expanding efficacy, Large addressable technology toxicity and markets Naturally derived manufacturing data where insecticide chemistry, with novel mode to support international resistance is a growing of action regulatory submis
Slide 12: Contact
BIO-GENE For personal use only TECHNOLOGY LIMITED ENABLING THE NEXT GENERATION OF NOVEL INSECTICIDES CONTACT RICHARD JAGGER CHIEF EXECUTIVE OFFICER richardj@bio-gene.com.au
Bio-Gene Technology — Investor Presentation (October 2021) on 6ix